Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 152
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Approved-not yet active
Not specified
Pharmaceutical / Industry
A6181171
NCT00684645
2.
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181132
NCT00706706
3.
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181177
NCT00793871
4.
SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181034
NCT00083889
5.
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181036
NCT00094029
6.
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181037
NCT00130897
Last Modified:
1/14/2009
 
First Published:
5/11/2006
7.
Phase III Randomized Study of Adjuvant Sunitinib Malate Versus Sorafenib in Patients With Resected Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
ECOG-E2805
E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
8.
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181109
NCT00375674
9.
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181094
NCT00373256
10.
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181064
NCT00393939
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute